Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population

1 Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: A Phase II trial (CTEP 7190/ Mel47) Clinical Cancer Research, April 26, 2013

2 Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10mg/kg within an expanded access programme Cancer Immunology, Immunotherapy, April 22, 2013

3 Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials Annals of Oncology, May 14, 2013

4 MERTK receptor tyrosine kinase is a therapeutic target in melanoma The Journal of Clinical Investigation, April 24, 2013

5 A randomized phase II trial of multi-epitope vaccination with melanoma peptides for cytotoxic T-cells and helper T-cells for patients with metastatic melanoma (E1602) Clinical Cancer Research, May 13, 2013

6 Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer Clinical Cancer Research, May 2, 2013

7 Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours British Journal of Cancer, May 8, 2013

8 Association between tuberculosis infections and non-pulmonary malignancies: a nationwide population-based study British Journal of Cancer, May 9, 2013

9 Antihyperglycemic Drug Gymnema sylvestre Also Shows Anticancer Potentials in Human Melanoma A375 Cells via Reactive Oxygen Species Generation and Mitochondria-Dependent Caspase Pathway Integrative Cancer Therapies , April 29, 2013

10 Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma Clinical and Experimental Dermatology, May 3, 2013